Companies Form Expert Working Group to Introduce Essential Tools for AAV Development and Research Professionals
SAN FRANCISCO / ACCESSWIRE / June 27, 2024 / Form Bio, the provider of advanced computational life sciences technology and PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a range of new initiatives aimed at advancing and unifying the AAV industry. The initiatives, including an AAV data dictionary, open-source tools and more, are being driven by a new AAV Working Group, jointly assembled by Form Bio and PacBio and composed of leading AAV experts across industry and academia. The resulting materials are being made available on a new AAV Resource Hub at aav.formbio.com.
AAV is widely recognized as one of the most promising technologies for gene therapy due to its non-pathogenic nature. However, collaboration on AAV-based programs is often hindered by industry silos that lead to divergent terminology and methods, which can differ widely between various companies and institutions operating at the forefront of AAV innovation. In addition, the lack of standard definitions and practices works against uniformity of regulatory submissions, making it harder and more time consuming for regulatory agencies to evaluate potential new therapies.
In response, Form Bio and PacBio have convened leading experts to form an AAV Working Group dedicated to developing and promoting standardized nomenclature and reporting practices to foster consistency and reliability in AAV research and development. The charter of the newly formed AAV Working Group is to develop standardized nomenclature, establish standardized reporting, and promote widespread adoption of these initiatives.
Members of the AAV Working Group include:
Nam Tonthat, Ph.D - Asklepios BioPharmaceutical
Pranam Chatterjee, Ph.D - Department of Biomedical Engineering, Duke University
Douglas McCarty, Ph.D - Nationwide Children's Hospital
Phillip W.L. Tai, Ph.D - Department of Microbiology and Physiological Systems, UMass Chan Medical School; Horae Gene Therapy Center, UMass Chan Medical School
Adam Cockrell, Ph.D - Solid Biosciences
Elizabeth Tseng, Ph.D - PacBio
Nadia Sellami, Ph.D - PacBio
Eric Talevich, Ph.D - Form Bio
Alpha Diallo, Ph.D - Form Bio
Amicia Elliott, Ph.D - Form Bio
Brandi Cantarel, Ph.D - Form Bio
Claire Aldridge, Ph.D - Form Bio
"Getting AAV-based gene therapies to the clinic requires speed and collaboration among many different parties. But it's become clear that speed and collaboration are being held back by the lack of a common language and practices in dealing with AAV vectors," said Claire Aldridge, Ph.D, chief strategy officer for Form Bio. "We see working with our partners at PacBio and bringing together leaders across academia and industry as a critical need in helping AAV-based gene therapies reach their fullest potential faster," she added.
"PacBio is thrilled to be part of this effort and partnering with Form Bio and leading experts in the field. The value of highly accurate long-read sequencing for gene therapy is clear, and we are excited to see how these resources help researchers develop the next generation of vectorsl," said Nadia Sellami, Ph.D, segment lead, cell and gene therapy for PacBio.
The AAV Working Group has generated several key, publicly available resources:
Preprint Publication: Standardized Nomenclature and Reporting for PacBio HiFi Sequencing and Analysis of rAAV Gene Therapy Vectors
Open Source Workflow: LAAVA (Long-read AAV Analysis)
Glossary of Terms: AAV Data Dictionary
Regulatory Case Study: Characterizing Drug Products with NGS
All of the above resources and more can be explored on the new AAV Resource Hub at aav.formbio.com.
These resources aim to streamline development processes and collaboration across the AAV industry. By fostering consistency and clarity in AAV research and development, Form Bio and PacBio are paving the way for more efficient and effective gene therapy solutions, ultimately benefiting patients worldwide.
To access these and other resources or to learn more about getting involved with the AAV Working Group, please visit aav.formbio.com.
About Form Bio
Form Bio provides award-winning software and AI solutions for cell and gene therapy leaders. By combining data, technology and expertise, Form's solutions accelerate timelines from discovery to clinic by providing drug developers with rapid in silico characterization, prediction, simulation and optimization of their therapeutics - enabling higher yields, enhanced safety and shorter, less-expensive development cycles. With cross-disciplinary expertise spanning software engineering, biology, bioinformatics and data science, the Form Bio team collaborates closely with customers on their most pressing and strategic challenges and opportunities. For more information, visit or follow the company at
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to PacBio's collaboration with Form Bio and the AAV Working Group; the potential benefits and impacts of the AAV Working Group; the benefits or potential benefits of AAV-based programs; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including the risk that PacBio's collaboration with Form Bio and the AAV Working Group may not be successful or deliver the benefits that PacBio currently anticipates. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
SAN FRANCISCO/ACCESSWIRE/2024年6月27日/PacBio(NASDAQ:PACB)の高品質で高精度なシークエンシングソリューションを提供する先進的なコンピュータライフサイエンス技術のプロバイダーであるForm Bioと、AAV業界を前進させるための新しい取り組み（AAVデータ辞書、オープンソースツールなど）を発表した。これにより、Form BioとPacBioによる新しいAAVワーキンググループが立ち上げられ、業界や学界の主要なAAV専門家から構成されている。これらの内容は、AAVリソースハブとして、aav.formbio.comで公開されている。
Pranam Chatterjee, Ph.D - Department of Biomedical Engineering, Duke University
Douglas McCarty, Ph.D - Nationwide Children's Hospital
Phillip W.L. Tai, Ph.D - Department of Microbiology and Physiological Systems, UMass Chan Medical School; Horae Gene Therapy Center, UMass Chan Medical School
これらのおよびその他のリソースにアクセスするか、AAV Working Groupに参加するには、aav.formbio.comを訪問してください。
フォームバイオについて
フォームバイオは、細胞および遺伝子治療リーダー向けの受賞歴を誇るソフトウェアおよびAIソリューションを提供しています。Formのソリューションは、データ、テクノロジー、および専門知識を組み合わせることで、薬剤開発者に急速な薬剤の特性、予測、シミュレーション、および最適化を提供することにより、発見からクリニックまでのタイムラインを加速します。これにより、高い収量、強化された安全性、およびより短く、より安価な開発サイクルが可能になります。ソフトウェアエンジニアリング、生物学、バイオインフォマティクス、およびデータサイエンスにわたる横断的な専門知識を備えたForm Bioチームは、顧客が最も重要で戦略的な課題や機会に対して密に協力しています。詳細については、 。in silicoこのプレスリリースには、改正された1934年証券取引法第21条、および1995年改正米国私的訴訟改革法に定められた「前向き見通しの声明」が含まれる場合があります。歴史的事実以外のすべての記述は将来に向けた積極的な声明です。PacBioのフォームバイオやAAV Working Groupとの協力、AAV Working Groupの潜在的な利益や影響、AAVベースのプログラムの利益または潜在的な利益、およびその他の将来のイベントに関する記述を含め、今後の見通しには極めて多くの不確実性があります。PacBioが現在予想している利益を提供しない場合があります。実際の結果が想定とは異なる場合があり、前向き見通しの声明に無条件に依存するべきではありません。実際の結果に重大な影響を与える要因を説明する追加因子は、最も最近の証券取引委員会へのPacBioの報告書、8-K、10-K、および10-Qを含めて、キャプション「リスクファクター」のリストに含まれる可能性があります。これらの前向き見通しの声明は現在の期待値に基づいており、ここでのみ当時の状況について述べています。法律により要求される場合を除き、PacBioはこれらの前向き見通しの声明を修正または更新して、将来のイベントまたは状況を反映することはありません。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会（ASIC）の管理を受けております（AFSL No. 224663）。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会（ASIC）の管理を受けております（AFSL No. 224663）。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
